A phase II study of MGI-114 [irofulven] in patients with recurrent or persistent epithelial ovarian cancer.
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2011
At a glance
- Drugs Irofulven (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 30 May 2007 New trial record.